- Gedatolisib Prolongs PFS in Advanced Breast Cancer Medscape
- Top 1% Celcuity Stock Shoots To Record High On Roche-Rivaling Breast Cancer Results Investor’s Business Daily
- Celcuity’s Promising Results: Time to Reassess? timothysykes.com
- Celcuity (CELC) Is Up 41.8% After Phase 3 Data Shows Gedatolisib Boosts Survival in Breast Cancer simplywall.st
- VIKTORIA-1 Trial: Post-CDK4/6 Therapy for Endocrine-Resistant Breast Cancer Targeted Oncology
Forensic CT helps medical examiners determine cause of death — and thus avoid autopsy, a procedure that can not only be upsetting for a decedent’s loved ones but also time-consuming for medical examiner staff, according to Kalpana Kanal, PhD, of…